FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4311451985> ?p ?o ?g. }

• W4311451985 endingPage "76" @default.
• W4311451985 startingPage "64" @default.
• W4311451985 abstract "Patients with newly diagnosed multiple myeloma and high-risk cytogenetic abnormalities (HRCA) represent an unmet medical need. In the FORTE trial, lenalidomide and dexamethasone plus carfilzomib (KRd) induction resulted in a higher proportion of patients with at least a very good partial response as compared with carfilzomib, cyclophosphamide, and dexamethasone (KCd), and carfilzomib plus lenalidomide maintenance prolonged progression-free survival compared with lenalidomide maintenance. In this prespecified analysis of the FORTE trial, we described the outcomes of enrolled patients according to their cytogenetic risk.The UNITO-MM-01/FORTE was a randomised, open-label, phase 2 trial done at 42 Italian academic and community practice centres, which enrolled transplant-eligible patients with newly diagnosed multiple myeloma aged 18-65 years. Eligible patients had newly diagnosed multiple myeloma based on standard International Myeloma Working Group criteria, a Karnofsky performance status of at least 60%, and had not received any previous treatment with anti-myeloma therapy. At enrolment, patients were stratified according to International Staging System stage (I vs II/III) and age (<60 years vs 60-65 years) and randomly assigned (1:1:1) to KRd plus autologous stem-cell transplantation (ASCT; four 28-day induction cycles with KRd, melphalan at 200 mg/m2 and ASCT [MEL200-ASCT], followed by four 28-day KRd consolidation cycles), 12 28-day KRd cycles, or KCd plus ASCT (four 28-day induction cycles with KCd, MEL200-ASCT, and four 28-day KCd consolidation cycles), using a web-based system (block randomisation, block size of 12). Carfilzomib was administered at 20 mg/m2 on days 1 and 2 of cycle 1, followed by 36 mg/m2 intravenously administered on days 8, 9, 15, and 16 of cycle 1, and then 36 mg/m2 intravenously administered for all subsequent doses on days 1, 2, 8, 9, 15, 16; lenalidomide 25 mg was administered orally on days 1-21; cyclophosphamide 300 mg/m2 was administered orally on days 1, 8, and 15; and dexamethasone 20 mg was administered orally or intravenously on days 1, 2, 8, 9, 15, 16, 22, and 23. After the consolidation phase, patients were stratified according to induction-consolidation treatment and randomly assigned (1:1; block size of 8) to maintenance treatment with carfilzomib plus lenalidomide or lenalidomide alone. Carfilzomib 36 mg/m2 was administered intravenously on days 1-2 and days 15-16, every 28 days for up to 2 years, and lenalidomide 10 mg was administered orally on days 1-21 every 28 days until progression or intolerance in both groups. The primary endpoints were the proportion of patients with at least a very good partial response after induction with KRd versus KCd and progression-free survival with carfilzomib plus lenalidomide versus lenalidomide alone as maintenance treatment. In this preplanned analysis, we included patients enrolled in the FORTE trial with complete cytogenetic data on del(17p), t(4;14), t(14;16), del(1p), gain(1q) (3 copies), and amp(1q) (≥4 copies) assessed by fluorescence in-situ hybridisation analysis on CD138-positive sorted cells. We assessed progression-free survival, overall survival, minimal residual disease negativity, and 1-year sustained minimal residual disease negativity according to the presence of zero, one, and two or more HRCA across treatment groups. The FORTE trial is ongoing, and registered with ClinicalTrials.gov, NCT02203643.Between Feb 23, 2015, and April 5, 2017, 477 patients were enrolled, of whom 396 (83%) had complete cytogenetic data and were analysed (176 [44%] of whom were women and 220 [56%] were men). The median follow-up from first randomisation was 51 months (IQR 46-56). 4-year progression-free survival was 71% (95% CI 64-78) in patients with zero HRCA, 60% (95% CI 52-69) in patients with one HRCA, and 39% (95% CI 30-50) in patients with two or more HRCA. Compared with patients with zero HRCA, the risk of progression or death was similar in patients with one HRCA (hazard ratio [HR] 1·33 [95% CI 0·90-1·97]; p=0·15) and higher in patients with two or more HRCA (HR 2·56 [95% CI 1·74-3·75]); p<0·0001) across the induction-intensification-consolidation groups. Moreover, the risk of progression or death was also higher in patients with two or more HRCA versus those with one HRCA (HR 1·92 [95% CI 1·34-2·76]; p=0·0004). 4-year overall survival from the first randomisation was 94% (95% CI 91-98) in patients with zero HRCA, 83% (95% CI 76-90) in patients with one HRCA, and 63% (95% CI 54-74) in patients with two or more HRCA. Compared with patients with zero HRCA, the risk of death was significantly higher in patients with one HRCA (HR 2·55 [95% CI 1·22-5·36]; p=0·013) and two or more HRCA (HR 6·53 [95% CI 3·24-13·18]; p<0·0001). Patients with two or more HRCA also had a significantly higher risk of death than those with one HRCA (HR 2·56 [95% CI 1·53-4·28]; p=0·0004). The rates of 1-year sustained minimal residual disease negativity were similar in patients with zero HRCA (53 [35%] of 153] and with one HRCA (57 [41%] of 138) and were lower in patients with two or more HRCA (25 [24%] of 105). The median duration of follow-up from second randomisation was 37 months (IQR 33-42). 3-year progression-free survival from the second randomisation was 80% (95% CI 74-88) in patients with zero HRCA, 68% (95% CI 59-78) in patients with one HRCA, and 53% (95% CI 42-67) in patients with two or more HRCA. The risk of progression or death was higher in patients with one HRCA (HR 1·68 [95% CI 1·01-2·80]; p=0·048) and two or more HRCA (2·74 [95% CI 1·60-4·69], p=0·0003) than in patients with zero HRCA.This preplanned analysis of the FORTE trial showed that carfilzomib-based induction-intensification-consolidation regimens are effective strategies in patients with standard risk (zero HRCA) and high-risk (one HRCA) myeloma, resulting in similar rates of progression-free survival and 1-year sustained minimal residual disease negativity. Despite promising progression-free survival, patients with ultra-high-risk disease (those with 2 or more HRCA) still have an increased risk of progression and death and therefore represent an unmet medical need.Amgen and Celgene/Bristol Myers Squibb." @default.
• W4311451985 created "2022-12-26" @default.
• W4311451985 creator A5004911570 @default.
• W4311451985 creator A5008923543 @default.
• W4311451985 creator A5010744664 @default.
• W4311451985 creator A5011678278 @default.
• W4311451985 creator A5018088896 @default.
• W4311451985 creator A5018139001 @default.
• W4311451985 creator A5019534037 @default.
• W4311451985 creator A5025049786 @default.
• W4311451985 creator A5025476428 @default.
• W4311451985 creator A5026829269 @default.
• W4311451985 creator A5028704583 @default.
• W4311451985 creator A5030188559 @default.
• W4311451985 creator A5031078901 @default.
• W4311451985 creator A5031758293 @default.
• W4311451985 creator A5042850515 @default.
• W4311451985 creator A5044869604 @default.
• W4311451985 creator A5051164378 @default.
• W4311451985 creator A5051231544 @default.
• W4311451985 creator A5053181448 @default.
• W4311451985 creator A5055543156 @default.
• W4311451985 creator A5069053301 @default.
• W4311451985 creator A5072928867 @default.
• W4311451985 creator A5077047252 @default.
• W4311451985 creator A5080280590 @default.
• W4311451985 creator A5083314734 @default.
• W4311451985 creator A5086668081 @default.
• W4311451985 creator A5090050942 @default.
• W4311451985 date "2023-01-01" @default.
• W4311451985 modified "2023-10-04" @default.
• W4311451985 title "Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial" @default.
• W4311451985 cites W1912299294 @default.
• W4311451985 cites W2028195916 @default.
• W4311451985 cites W2128192762 @default.
• W4311451985 cites W2140568894 @default.
• W4311451985 cites W2142368474 @default.
• W4311451985 cites W2144728882 @default.
• W4311451985 cites W2318069817 @default.
• W4311451985 cites W2345005763 @default.
• W4311451985 cites W2478932238 @default.
• W4311451985 cites W2486629951 @default.
• W4311451985 cites W2766948867 @default.
• W4311451985 cites W2808202754 @default.
• W4311451985 cites W2885454329 @default.
• W4311451985 cites W2893245372 @default.
• W4311451985 cites W2904294860 @default.
• W4311451985 cites W2904778784 @default.
• W4311451985 cites W2913092224 @default.
• W4311451985 cites W2946678353 @default.
• W4311451985 cites W2948728876 @default.
• W4311451985 cites W2990816134 @default.
• W4311451985 cites W3017057237 @default.
• W4311451985 cites W3021098306 @default.
• W4311451985 cites W3022981424 @default.
• W4311451985 cites W3048382072 @default.
• W4311451985 cites W3113412439 @default.
• W4311451985 cites W3119465382 @default.
• W4311451985 cites W3136388199 @default.
• W4311451985 cites W3209897673 @default.
• W4311451985 cites W3211471574 @default.
• W4311451985 cites W3212617436 @default.
• W4311451985 cites W4200312283 @default.
• W4311451985 cites W4225943158 @default.
• W4311451985 cites W4281397013 @default.
• W4311451985 cites W4281628749 @default.
• W4311451985 doi "https://doi.org/10.1016/s1470-2045(22)00693-3" @default.
• W4311451985 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36528035" @default.
• W4311451985 hasPublicationYear "2023" @default.
• W4311451985 type Work @default.
• W4311451985 citedByCount "12" @default.
• W4311451985 countsByYear W43114519852023 @default.
• W4311451985 crossrefType "journal-article" @default.
• W4311451985 hasAuthorship W4311451985A5004911570 @default.
• W4311451985 hasAuthorship W4311451985A5008923543 @default.
• W4311451985 hasAuthorship W4311451985A5010744664 @default.
• W4311451985 hasAuthorship W4311451985A5011678278 @default.
• W4311451985 hasAuthorship W4311451985A5018088896 @default.
• W4311451985 hasAuthorship W4311451985A5018139001 @default.
• W4311451985 hasAuthorship W4311451985A5019534037 @default.
• W4311451985 hasAuthorship W4311451985A5025049786 @default.
• W4311451985 hasAuthorship W4311451985A5025476428 @default.
• W4311451985 hasAuthorship W4311451985A5026829269 @default.
• W4311451985 hasAuthorship W4311451985A5028704583 @default.
• W4311451985 hasAuthorship W4311451985A5030188559 @default.
• W4311451985 hasAuthorship W4311451985A5031078901 @default.
• W4311451985 hasAuthorship W4311451985A5031758293 @default.
• W4311451985 hasAuthorship W4311451985A5042850515 @default.
• W4311451985 hasAuthorship W4311451985A5044869604 @default.
• W4311451985 hasAuthorship W4311451985A5051164378 @default.
• W4311451985 hasAuthorship W4311451985A5051231544 @default.
• W4311451985 hasAuthorship W4311451985A5053181448 @default.
• W4311451985 hasAuthorship W4311451985A5055543156 @default.
• W4311451985 hasAuthorship W4311451985A5069053301 @default.
• W4311451985 hasAuthorship W4311451985A5072928867 @default.
• W4311451985 hasAuthorship W4311451985A5077047252 @default.
• W4311451985 hasAuthorship W4311451985A5080280590 @default.
• W4311451985 hasAuthorship W4311451985A5083314734 @default.

• next